Minimally invasive glaucoma surgery (MIGS): XEN implant
Article Sidebar
Published:
Mar 31, 2019
Keywords:
glaucoma, minimally invasive glaucoma surgery, XEN implant
Main Article Content
Abstract
Despite all the advances in medicine, still the only proven way of glaucoma treatment is lowering intraocular pressure. Among therapeutic options, filtration surgery is one of the most effective procedures, but its safety profile is quite low. Today, minimally invasive techniques give hope that achieving the target intraocular pressure with less surgical complications is possible. XEN® implant proves to be effective in lowering intraocular pressure with high safety profile of the implantation procedure.
Downloads
Download data is not yet available.
Article Details
How to Cite
1.
Pożarowska D, Żarnowski T. Minimally invasive glaucoma surgery (MIGS): XEN implant. Ophthatherapy [Internet]. 2019Mar.31 [cited 2024Apr.24];6(1):18-3. Available from: https://www.journalsmededu.pl/index.php/ophthatherapy/article/view/505
Issue
Section
Articles
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
Copyright: © Medical Education sp. z o.o. License allowing third parties to copy and redistribute the material in any medium or format and to remix, transform, and build upon the material, provided the original work is properly cited and states its license.
Address reprint requests to: Medical Education, Marcin Kuźma (marcin.kuzma@mededu.pl)
References
1. Tham YC, Li X, Wong TY et al. Global prevalence of glaucoma and projections of glaucoma burden through 2040: a systematic review and meta-analysis. Ophthalmology. 2014; 121(11): 2081-90.
2. Europejskie Towarzystwo Jaskrowe. Zasady i metody leczenia. Terminologia i wytyczne postępowania w jaskrze. Wyd. IV. EGS 2016.
3. Heijl A, Leske MC, Bengtsson B et al.; Early Manifest Glaucoma Trial Group. Reduction of intraocular pressure and glaucoma progression: results from the Early Manifest Glaucoma Trial. Arch Ophthalmol. 2002; 120(10): 1268-79.
4. Gedde SJ, Schiffman JC, Feuer WJ et al.; Tube versus Trabeculectomy Study Group. Treatment outcomes in the Tube Versus Trabeculectomy (TVT) study after five years of follow-up. Am J Ophthalmol. 2012; 153(5): 789-803.e2.
5. Chaudhary A, Salinas L, Guidotti J et al. XEN Gel Implant: a new surgical approach in glaucoma. Expert Rev Med Devices. 2018; 15(1): 47-59.
6. Gedde SJ, Herndon LW, Brandt JD et al.; Tube Versus Trabeculectomy Study Group. Postoperative complications in the Tube Versus Trabeculectomy (TVT) study during five years of follow-up. Am J Ophthalmol. 2012; 153(5): 804-14.e1.
7. Kerr NM, Wang J, Barton K. Minimally invasive glaucoma surgery as primary stand-alone surgery for glaucoma. Clin Exp Ophthalmol. 2017; 45(4): 393-400.
8. Pillunat LE, Erb C, Jünemann AG et al. Micro-invasive glaucoma surgery (MIGS): a review of surgical procedures using stents. Clin Ophthalmol. 2017; 11: 1583-600.
9. Lavia C, Dallorto L, Maule M et al. Minimally-invasive glaucoma surgeries (MIGS) for open angle glaucoma: A systematic review and meta-analysis. PLoS One. 2017; 12(8): e0183142.
10. Chatzara A, Chronopoulou I, Theodossiadis G et al. XEN Implant for Glaucoma Treatment: A Review of the Literature. Semin Ophthalmol. 2019; 34(2): 93-7.
11. Midha N, Rao HL, Mermoud A et al. Identifying the predictors of needling after XEN gel implant. Eye (Lond). 2019; 33(3): 353-7.
12. Yadav KS, Sharma S. Implantable drainage devices in glaucoma: Quo vadis? Eur J Pharm Sci. 2019; 133: 1-7.
13. Lenzhofer M, Strohmaier C, Hohensinn M et al. Longitudinal bleb morphology in anterior segment OCT after minimally invasive transscleral ab interno Glaucoma Gel Microstent implantation. Acta Ophthalmol. 2019; 97(2): e231-7.
14. Ibáñez-Muñoz A, Soto-Biforcos VS, Chacón-González M et al. One-year follow-up of the XEN® implant with mitomycin-C in pseudoexfoliative glaucoma patients. Eur J Ophthalmol. 2018: 1120672118795063.
15. Mansouri K, Gillmann K, Rao HL et al. Prospective Evaluation of XEN Gel Implant in Eyes With Pseudoexfoliative Glaucoma. J Glaucoma. 2018; 27(10): 869-73.
16. Karimi A, Hopes M, Martin KR et al. Efficacy and Safety of the Ab-interno Xen Gel Stent After Failed Trabeculectomy. J Glaucoma. 2018; 27(10): 864-8.
17. Tailor R, Lalias T. A Case of Refractory Neovascular Glaucoma Treated With a XEN 45 Implant. J Glaucoma. 2018; 27(10): 929-30.
18. Marques RE, Ferreira NP, Sousa DC et al. Glaucoma Gel Implant Learning Curve in a Teaching Tertiary Hospital. J Glaucoma. 2019; 28(1): 56-60.
19. Arnould L, Theillac V, Moran S et al. Recurrent Exposure of XEN Gel Stent Implant and Conjunctival Erosion. J Glaucoma. 2019; 28(3): e37-40.
20. Montolío Marzo S, Lanzagorta Aresti A, Davó Cabrera JM et al. Malignant glaucoma after XEN45 implant. Arch Soc Esp Oftalmol. 2019; 94(3): 134-7.
21. Karimi A, Lindfield D, Turnbull A et al. A multi-centre interventional case series of 259 ab-interno Xen gel implants for glaucoma, with and without combined cataract surgery. Eye (Lond). 2019; 33(3): 469-77.
22. Olgun A, Imamoğlu S, Karapapak M et al. Endophthalmitis After XEN Gel Stent Implantation: 2 Cases. J Glaucoma. 2018; 27(12): e191-4.
23. Smith M, Charles R, Abdel-Hay A et al. 1-year outcomes of the Xen45 glaucoma implant. Eye (Lond). 2019; 33(5): 761-6.
24. Mansouri K, Guidotti J, Rao HL et al. Prospective Evaluation of Standalone XEN Gel Implant and Combined Phacoemulsification-XEN Gel Implant Surgery: 1-Year Results. J Glaucoma. 2018; 27(2): 140-7.
25. Galal A, Bilgic A, Eltanamly R et al. XEN Glaucoma Implant with Mitomycin C 1-Year Follow-Up: Result and Complications. J Ophthalmol. 2017; 2017: 5457246.
26. Reitsamer H, Sng C, Vera V et al.; Apex Study Group. Two-year results of a multicenter study of the ab interno gelatin implant in medically uncontrolled primary open-angle glaucoma. Graefes Arch Clin Exp Ophthalmol. 2019; 257(5): 983-96.
27. De Gregorio A, Pedrotti E, Russo L et al. Minimally invasive combined glaucoma and cataract surgery: clinical results of the smallest ab interno gel stent. Int Ophthalmol. 2018; 38(3): 1129-34.
28. Schlenker MB, Gulamhusein H, Conrad-Hengerer I et al. Efficacy, Safety, and Risk Factors for Failure of Standalone Ab Interno Gelatin Microstent Implantation versus Standalone Trabeculectomy. Ophthalmology. 2017; 124(11): 1579-88.
29. Laroche D, Ng C, Lynch G. Baerveldt Attached to XEN: A New Technique to Manage Failed XEN Glaucoma Surgery. J Glaucoma. 2018; 27(4): 382-4.
30. Ansari E. An Update on Implants for Minimally Invasive Glaucoma Surgery (MIGS). Ophthalmol Ther. 2017; 6(2): 233-41.
2. Europejskie Towarzystwo Jaskrowe. Zasady i metody leczenia. Terminologia i wytyczne postępowania w jaskrze. Wyd. IV. EGS 2016.
3. Heijl A, Leske MC, Bengtsson B et al.; Early Manifest Glaucoma Trial Group. Reduction of intraocular pressure and glaucoma progression: results from the Early Manifest Glaucoma Trial. Arch Ophthalmol. 2002; 120(10): 1268-79.
4. Gedde SJ, Schiffman JC, Feuer WJ et al.; Tube versus Trabeculectomy Study Group. Treatment outcomes in the Tube Versus Trabeculectomy (TVT) study after five years of follow-up. Am J Ophthalmol. 2012; 153(5): 789-803.e2.
5. Chaudhary A, Salinas L, Guidotti J et al. XEN Gel Implant: a new surgical approach in glaucoma. Expert Rev Med Devices. 2018; 15(1): 47-59.
6. Gedde SJ, Herndon LW, Brandt JD et al.; Tube Versus Trabeculectomy Study Group. Postoperative complications in the Tube Versus Trabeculectomy (TVT) study during five years of follow-up. Am J Ophthalmol. 2012; 153(5): 804-14.e1.
7. Kerr NM, Wang J, Barton K. Minimally invasive glaucoma surgery as primary stand-alone surgery for glaucoma. Clin Exp Ophthalmol. 2017; 45(4): 393-400.
8. Pillunat LE, Erb C, Jünemann AG et al. Micro-invasive glaucoma surgery (MIGS): a review of surgical procedures using stents. Clin Ophthalmol. 2017; 11: 1583-600.
9. Lavia C, Dallorto L, Maule M et al. Minimally-invasive glaucoma surgeries (MIGS) for open angle glaucoma: A systematic review and meta-analysis. PLoS One. 2017; 12(8): e0183142.
10. Chatzara A, Chronopoulou I, Theodossiadis G et al. XEN Implant for Glaucoma Treatment: A Review of the Literature. Semin Ophthalmol. 2019; 34(2): 93-7.
11. Midha N, Rao HL, Mermoud A et al. Identifying the predictors of needling after XEN gel implant. Eye (Lond). 2019; 33(3): 353-7.
12. Yadav KS, Sharma S. Implantable drainage devices in glaucoma: Quo vadis? Eur J Pharm Sci. 2019; 133: 1-7.
13. Lenzhofer M, Strohmaier C, Hohensinn M et al. Longitudinal bleb morphology in anterior segment OCT after minimally invasive transscleral ab interno Glaucoma Gel Microstent implantation. Acta Ophthalmol. 2019; 97(2): e231-7.
14. Ibáñez-Muñoz A, Soto-Biforcos VS, Chacón-González M et al. One-year follow-up of the XEN® implant with mitomycin-C in pseudoexfoliative glaucoma patients. Eur J Ophthalmol. 2018: 1120672118795063.
15. Mansouri K, Gillmann K, Rao HL et al. Prospective Evaluation of XEN Gel Implant in Eyes With Pseudoexfoliative Glaucoma. J Glaucoma. 2018; 27(10): 869-73.
16. Karimi A, Hopes M, Martin KR et al. Efficacy and Safety of the Ab-interno Xen Gel Stent After Failed Trabeculectomy. J Glaucoma. 2018; 27(10): 864-8.
17. Tailor R, Lalias T. A Case of Refractory Neovascular Glaucoma Treated With a XEN 45 Implant. J Glaucoma. 2018; 27(10): 929-30.
18. Marques RE, Ferreira NP, Sousa DC et al. Glaucoma Gel Implant Learning Curve in a Teaching Tertiary Hospital. J Glaucoma. 2019; 28(1): 56-60.
19. Arnould L, Theillac V, Moran S et al. Recurrent Exposure of XEN Gel Stent Implant and Conjunctival Erosion. J Glaucoma. 2019; 28(3): e37-40.
20. Montolío Marzo S, Lanzagorta Aresti A, Davó Cabrera JM et al. Malignant glaucoma after XEN45 implant. Arch Soc Esp Oftalmol. 2019; 94(3): 134-7.
21. Karimi A, Lindfield D, Turnbull A et al. A multi-centre interventional case series of 259 ab-interno Xen gel implants for glaucoma, with and without combined cataract surgery. Eye (Lond). 2019; 33(3): 469-77.
22. Olgun A, Imamoğlu S, Karapapak M et al. Endophthalmitis After XEN Gel Stent Implantation: 2 Cases. J Glaucoma. 2018; 27(12): e191-4.
23. Smith M, Charles R, Abdel-Hay A et al. 1-year outcomes of the Xen45 glaucoma implant. Eye (Lond). 2019; 33(5): 761-6.
24. Mansouri K, Guidotti J, Rao HL et al. Prospective Evaluation of Standalone XEN Gel Implant and Combined Phacoemulsification-XEN Gel Implant Surgery: 1-Year Results. J Glaucoma. 2018; 27(2): 140-7.
25. Galal A, Bilgic A, Eltanamly R et al. XEN Glaucoma Implant with Mitomycin C 1-Year Follow-Up: Result and Complications. J Ophthalmol. 2017; 2017: 5457246.
26. Reitsamer H, Sng C, Vera V et al.; Apex Study Group. Two-year results of a multicenter study of the ab interno gelatin implant in medically uncontrolled primary open-angle glaucoma. Graefes Arch Clin Exp Ophthalmol. 2019; 257(5): 983-96.
27. De Gregorio A, Pedrotti E, Russo L et al. Minimally invasive combined glaucoma and cataract surgery: clinical results of the smallest ab interno gel stent. Int Ophthalmol. 2018; 38(3): 1129-34.
28. Schlenker MB, Gulamhusein H, Conrad-Hengerer I et al. Efficacy, Safety, and Risk Factors for Failure of Standalone Ab Interno Gelatin Microstent Implantation versus Standalone Trabeculectomy. Ophthalmology. 2017; 124(11): 1579-88.
29. Laroche D, Ng C, Lynch G. Baerveldt Attached to XEN: A New Technique to Manage Failed XEN Glaucoma Surgery. J Glaucoma. 2018; 27(4): 382-4.
30. Ansari E. An Update on Implants for Minimally Invasive Glaucoma Surgery (MIGS). Ophthalmol Ther. 2017; 6(2): 233-41.